In our work, we have analyzed the activity of the combination between standard-of-care chemotherapeutics used in CRC and niraparib in a panel of 12 cell lines that encompasses the 4 consensus molecular subtypes, the different microsatellite status, and the different KRAS and BRAF mutational profiles. Here, BRAF is linked to colorectal carcinoma.